發(fā)布時(shí)間：2018-08-17 20:07

【摘要】：“十三五”規(guī)劃將醫(yī)藥產(chǎn)業(yè)劃為重點(diǎn)發(fā)展產(chǎn)業(yè)之一。新藥研發(fā)是醫(yī)藥產(chǎn)業(yè)發(fā)展的原動(dòng)力,而研發(fā)成果的轉(zhuǎn)化依賴于對(duì)未來(lái)收益的可靠計(jì)量與評(píng)估,因此新藥研發(fā)的評(píng)估構(gòu)成了醫(yī)藥產(chǎn)業(yè)發(fā)展的重要組成部分,對(duì)新藥研發(fā)價(jià)值的評(píng)估也成為了當(dāng)前整個(gè)行業(yè)關(guān)注的重點(diǎn)領(lǐng)域。本文重點(diǎn)研究?jī)?nèi)容即是新藥研究?jī)r(jià)值評(píng)估過(guò)程所涉及的評(píng)估方法。在進(jìn)行資產(chǎn)評(píng)估時(shí)常使用的辦法主要有三種,即市場(chǎng)法、收益法和成本法,即使傳統(tǒng)辦法各有特點(diǎn),但面對(duì)某些特定對(duì)象如新藥研發(fā)時(shí),傳統(tǒng)方法并不能發(fā)揮很好的作用。成本法中研發(fā)成本的研究成果存在弱對(duì)稱性,導(dǎo)致評(píng)估結(jié)果的實(shí)際價(jià)值差異明顯。市場(chǎng)法中可比案例缺乏,因?yàn)槭袌?chǎng)法中可作為可比案例的基礎(chǔ)相當(dāng)薄弱。收益法中新藥研發(fā)價(jià)值的收益存在不確定性,這些都導(dǎo)致傳統(tǒng)方法無(wú)法適用于該類資產(chǎn)的評(píng)估。本文在對(duì)情景分析法的實(shí)質(zhì)分析基礎(chǔ)上,著重探討了決策樹(shù)法的具體運(yùn)用,構(gòu)建了該方法的測(cè)算模型,并就參數(shù)選擇做了具體的說(shuō)明。特別折現(xiàn)率、成功率、自由現(xiàn)金流以及階段時(shí)間的劃分等這些參數(shù)的求取。做了充分的論證闡述。并在文章的后半部分采用實(shí)際案例進(jìn)行說(shuō)明,將理論與實(shí)際應(yīng)用相結(jié)合,闡釋該方法的具體應(yīng)用。本文的結(jié)論得出情景分析法可應(yīng)用于新藥研發(fā)的價(jià)值評(píng)估,不足之處是該方法的參數(shù)測(cè)算具有一定的主觀性,前期成本需要估算實(shí)際發(fā)生的成本,這對(duì)該方法的運(yùn)用存在一定的限制。該類問(wèn)題將是本文后續(xù)研究的內(nèi)容。
[Abstract]:The 13 th-5-year-plan classifies the pharmaceutical industry as one of the key development industries. Research and development of new drugs is the driving force of the development of pharmaceutical industry, and the transformation of research and development results depends on the reliable measurement and evaluation of future benefits. Therefore, the evaluation of new drug research and development constitutes an important part of the development of the pharmaceutical industry. Evaluation of the value of new drug research and development has become the current focus of the industry. This paper focuses on the evaluation methods involved in the evaluation process of new drug research value. There are mainly three methods used in asset evaluation, namely, market approach, income approach and cost method. Although the traditional methods have their own characteristics, the traditional methods can not play a good role in the face of some specific objects, such as the research and development of new drugs. There is a weak symmetry in the research results of R & D cost in cost method, which leads to the difference of the actual value of the evaluation results. There is a lack of comparable cases in market law because the basis for comparable cases in market law is rather weak. There is uncertainty about the value of new drug research and development in the income approach, which leads to the traditional method can not be applied to the evaluation of this kind of assets. Based on the analysis of the essence of scenario analysis, this paper mainly discusses the application of decision tree method, constructs the measuring model of this method, and explains the selection of parameters in detail. Special discount rate, success rate, free cash flow and the division of stage time are obtained. A full demonstration is made. In the second half of this paper, a practical case is used to explain the concrete application of the method by combining the theory with the practical application. The conclusion of this paper is that scenario analysis can be used to evaluate the value of new drug research and development. There are some limitations on the application of this method. This kind of problem will be the content of the following research in this paper.
【學(xué)位授予單位】：江西財(cái)經(jīng)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：F406.7;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 閆凱;李認(rèn)書;周水平;李云飛;孫鶴;;實(shí)物期權(quán)法在新藥研發(fā)項(xiàng)目?jī)r(jià)值評(píng)估中的應(yīng)用[J];項(xiàng)目管理技術(shù);2012年09期

2 王知津;周鵬;韓正彪;;基于情景分析法的企業(yè)危機(jī)發(fā)展預(yù)測(cè)[J];圖書館論壇;2010年06期

3 朱燕萍;;決策樹(shù)法在企業(yè)決策中的應(yīng)用[J];企業(yè)導(dǎo)報(bào);2009年02期

4 倪亞飛;;基于二叉樹(shù)的實(shí)物期權(quán)法在新藥研發(fā)中的應(yīng)用研究[J];技術(shù)與創(chuàng)新管理;2009年01期

5 王茜;;基于實(shí)物期權(quán)理論的醫(yī)藥生物企業(yè)研發(fā)投資特性分析[J];科學(xué)學(xué)與科學(xué)技術(shù)管理;2008年02期

6 曹麗;;淺析資本預(yù)算中的凈現(xiàn)值法[J];財(cái)會(huì)月刊;2007年27期

7 趙修衛(wèi);舒文靜;;實(shí)物期權(quán)法與凈現(xiàn)值法在R&D項(xiàng)目評(píng)價(jià)中的比較[J];中國(guó)資產(chǎn)評(píng)估;2006年09期

8 趙振武;唐萬(wàn)生;;模糊實(shí)物期權(quán)理論在風(fēng)險(xiǎn)投資項(xiàng)目?jī)r(jià)值評(píng)價(jià)中的應(yīng)用[J];北京理工大學(xué)學(xué)報(bào)(社會(huì)科學(xué)版);2006年01期

9 于紅霞;錢榮;;解讀未來(lái)發(fā)展不確定性的情景分析法[J];未來(lái)與發(fā)展;2006年02期

10 許群英;曾勇;蔡強(qiáng);;實(shí)物期權(quán)在新藥開(kāi)發(fā)中的應(yīng)用[J];運(yùn)籌與管理;2005年06期

相關(guān)博士學(xué)位論文 前1條

1 楊莉;藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)需求、方法與指南研究[D];復(fù)旦大學(xué);2004年

相關(guān)碩士學(xué)位論文 前2條

1 周麗麗;模糊實(shí)物期權(quán)在R&D項(xiàng)目評(píng)價(jià)中的應(yīng)用[D];華中科技大學(xué);2012年

2 郭軍;基于模糊實(shí)物期權(quán)的風(fēng)險(xiǎn)投資決策研究[D];南京航空航天大學(xué);2008年

，

本文編號(hào)：2188757